NCT00002913View on ClinicalTrials.gov

Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 1996

Primary Completion Date

July 31, 2007

Conditions
Brenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mixed Epithelial CarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated AdenocarcinomaStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
Interventions
DRUG

paclitaxel

Given IV

DRUG

cisplatin

Given IV

DRUG

topotecan hydrochloride

Given IV

BIOLOGICAL

filgrastim

Given SC

Trial Locations (1)

85012

Gynecologic Oncology Group of Arizona, Phoenix

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00002913 - Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter